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Summary and Conclusion
• These results support cemiplimab as a standard of care option for treatment of 
advanced CSCC, with clinically meaningful benefits on HRQoL and clinically 
meaningful reductions in pain that appear to be independent of opioid use and 
may correlate with tumor response.
Synopsis
• Patients with advanced cutaneous squamous cell carcinoma (CSCC) who are not 
curable by surgery are generally administered palliative systemic therapy.
 - In these patients, pain is an important symptom from the patient and clinician 
perspectives.1
• Cemiplimab is indicated for treatment of patients with metastatic CSCC (mCSCC) or 
locally advanced CSCC (laCSCC) not eligible for curative surgery/radiation.2
• Cemiplimab demonstrated a robust clinical response and a safety profile consistent 
with other checkpoint inhibitors.3
• A Phase 2 clinical trial supported durability of response and reported an overall 
objective response rate (ORR) of 46.1%4-6 as measured by Response Evaluation 
Criteria in Solid Tumors version 1.1 (RECIST 1.1).7
• The Phase 2 trial included the cancer-specific European Organisation for Research 
and Treatment of Cancer (EORTC) 30-item questionnaire (QLQ-C30)8 as a measure  
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Figure 1. Proportion of patients reporting clinically meaningful change at cycle 6 
and cycle 12
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350 mg Q3W 
(n=56)
mCSCC  
3 mg/kg Q2W 
(n=59)
laCSCC  
3 mg/kg Q2W 
(n=78)
Age, mean ± SD, years 71.1 ± 11.4 69.7 ± 12.8 70.4 ± 10.1 72.5 ± 11.2
≥65 years, n (%) 144 (74.6) 42 (75.0) 43 (72.9) 59 (75.6)
Male, n (%) 161 (83.4) 48 (85.7) 54 (91.5) 59 (75.6)
ECOG performance status, n (%)
0 86 (44.6) 25 (44.6) 23 (39.0) 38 (48.7)
1 107 (55.4) 31 (55.4) 36 (61.0) 40 (51.3)
Primary site, n (%)
Head and neck 131 (67.9) 31 (55.4) 38 (64.4) 62 (79.5)
Other 62 (32.1) 25 (44.6) 21 (35.6) 16 (20.5)
Prior cancer-related 
systemic therapy, n (%) 65 (33.7) 20 (35.7) 33 (55.9) 12 (15.4)
Prior cancer-related 
radiotherapy, n (%) 131 (67.9) 38 (67.9) 50 (84.7) 43 (55.1)
SD, standard deviation.
• Clinically meaningful improvement or stability was experienced by 77%–86% of 
patients across QLQ-C30 scales by cycle 6, and by 74%–95% at cycle 12 (Figure 1).























































137 125 105 105 101 84 73 65 59 52 43N=152Total
57 47 35 33 29 25 23 18 15 12 7n=67Clinical non-responders
80 78 70 72 72 59 50 47 44 40 36n=85Clinicalresponder



































Figure 2. Change from baseline in QLQ-C30 pain score by cycle among patients 
who had baseline and post-baseline assessment of the QLQ-C30 pain scale

































































Figure 3. Cumulative number of days on opioids over time among patients who had 
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Figure 4. KM survival analysis of time to first clinically meaningful improvement in 
pain score (A) and first tumor response (B)
Time point where horizontal broken line (50% survival probability) crosses curve indicates median time to response.
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Figure 5. KM survival analysis of time to first clinically meaningful deterioration in 
pain score (A) and PFS (B)
Time point where horizontal broken line (50% survival probability) crosses curve indicates median time to response.
Table 3. Summary of relationship between clinically meaningful changes in pain and 









Baseline pain score, mean ± SD (n) 26.5 ± 29.1 (85) 33.7 ± 31.1 (83) 30.1 ± 30.3 (168)
Change from baseline in pain score  
at first tumor response, n 85 67 —
LS mean change ± SE –15.2 ± 1.5† –3.9 ± 2.1 —
LS mean (95% CI) difference vs  
non-responders 
–11.3
(–16.3, –6.3)‡ — —
Median time to clinical response, months (n) 2.0 (85) — —
Median PFS, months (n) — — 18.4 (193)
Median time to first pain improvement, 
months (n) 2.1 (53) — 2.1 (100)
Median time to first pain deterioration, 
months (n) 20.6 (80) — 14.8 (142)
*Ns reflect the number of patients who had baseline and post-baseline assessment scores on the QLQ-C30 pain scale.  
†P<0.0001 relative to baseline; ‡P<0.0001 compared with non-responders.
• Since pain medication use was captured over treatment duration, opioids were 
analyzed at each cycle.
 - Opioid use was adjusted for duration to calculate cumulative number of days on 
opioids per patient-year using Poisson regression with treatment group as fixed 
factors and patients’ treatment exposure duration as offset variable.
Table 2. Baseline scores and change from baseline (MMRM) in patients in the full 
analysis set who had baseline and post-baseline assessments on each QLQ-C30 
scale or item
QLQ-C30 scale/item Baseline, mean ± SD (n) LS mean change ± SE (n)
Cycle 3 Cycle 12
Global Health Status/HRQoL 65.1 ± 22.9 (150) 7.8 ± 1.6 (122)** 11.1 ± 2.6 (43)**
Functional scales†
Physical function 80.1 ± 22.8 (151) 1.1 ± 1.3 (124) 4.0 ± 2.1 (43)
Role function 75.8 ± 30.0 (151) 0.4 ± 2.1 (123) 5.6 ± 3.4 (43)
Emotional function 80.2 ± 21.2 (151) 4.2 ± 1.3 (123)* 5.3 ± 2.2 (43)*
Cognitive function 83.4 ± 22.2 (151) 1.7 ± 1.4 (123) 2.5 ± 2.3 (43)
Social function 74.4 ± 31.8 (150) 5.3 ± 1.8 (122)* 8.6 ± 3.0 (43)*
Symptoms‡
Fatigue 30.2 ± 24.6 (152) –2.8 ± 1.7 (125) –4.8 ± 2.8 (43)
Nausea/vomiting 4.6 ± 12.2 (152) –1.6 ± 0.8 (125)* –2.9 ± 1.3 (43)*
Pain 29.8 ± 30.4 (152) –11.5 ± 1.9 (125)** –14.3 ± 3.1 (43)**
Dyspnea 12.9 ± 23.4 (152) 0.7 ± 1.7 (125) 1.5 ± 2.9 (43)
Insomnia 27.4 ± 28.0 (151) –9.1 ± 2.0 (123)** –17.4 ± 3.3 (43)**
Appetite loss 19.5 ± 29.3 (152) –8.4 ± 1.6 (124)** –13.7 ± 2.7 (43)**
Constipation 13.6 ± 24.1 (152) –4.5 ± 1.5 (125)* –11.2 ± 2.5 (43)**
Diarrhea 4.9 ± 13.6 (150) 3.6 ± 1.4 (121)* 0.6 ± 2.3 (43)
Financial difficulty 19.1 ± 30.7 (150) 0.5 ± 2.0 (122) –3.4 ± 3.3 (43)
**P<0.001 and *P<0.05 versus baseline. †Higher scores reflect better outcomes. ‡Lower scores reflect better outcomes.
• Baseline scores indicated moderate to high levels of functioning and moderate to low 
symptom burden (Table 2).
• At cycle 3, significant improvements from baseline were observed for emotional and 
social function and symptoms of pain, insomnia, appetite loss, nausea/vomiting,  
and constipation (all P<0.05) (Table 2).
• Improvements increased or were maintained at cycle 12 and were clinically 
meaningful for pain, insomnia, appetite loss, and constipation (Table 2).
• These improvements likely contributed to the improved HRQoL that was significant at 
cycle 3 (P<0.001) and clinically meaningful at cycle 12.
• In all patients, reductions from baseline in pain were statistically significant as early as 
cycle 2, clinically meaningful by cycle 3, and sustained to cycle 12 (Figure 2).
• In contrast to clinical non-responders, clinical responders reported a clinically 
meaningful reduction in pain from baseline at cycle 2 with further reductions that were 
sustained to cycle 12 (all P<0.0001) (Figure 2).
• Opioid use decreased over study duration (Figure 3), suggesting that clinically 
meaningful improvement in pain was independent of opioid use.
• Median time to first clinically meaningful pain improvement in all patients 
approximated the median time to first tumor response that was estimated for clinical 
responders, 2.0 months and 2.1 months, respectively (Figure 4; Table 3).
 - Among clinical responders, the median time to first clinically meaningful pain 
improvement was also 2.1 months.
• The change from baseline in pain score at first tumor response was statistically 
significant and clinically meaningful versus non-responders (P<0.0001) (Table 3).
Study Limitations
• This was a single-arm, open-label study.
• The 10-point threshold considered indicative of a clinically meaningful change has not 
been validated for this patient population (i.e., advanced CSCC).
• Median time to first clinically meaningful deterioration in pain approximated the median 
time to progression-free survival (PFS), 14.8 months and 18.4 months, respectively 
(Figure 5; Table 3).
 - Median time to first clinically meaningful pain deterioration among clinical 
responders was 20.6 months (Table 3).
Objective
• This post hoc analysis explored the effects of cemiplimab on HRQoL and pain using 
QLQ-C30 data from the Phase 2 clinical trial (NCT02760498) of advanced CSCC, with 
a focus on the association between time to clinically meaningful changes in pain and 
clinical tumor response.
Methods
• For inclusion in this non-randomized, global, pivotal trial, adults with advanced CSCC 
not amenable to curative surgery/radiotherapy according to the investigator were  
required to have ≥1 lesion, Eastern Cooperative Oncology Group (ECOG) performance 
status ≤1, and life expectancy >12 weeks.
• Patients (N=193) received intravenous cemiplimab 3 mg/kg every 2 weeks (Q2W; 
mCSCC n=59; laCSCC n=78) for 12 treatment cycles or 350 mg every 3 weeks  
(Q3W; mCSCC n=56) for six treatment cycles.
 - Treatment cycle length was 8 weeks for the Q2W groups and 9 weeks for the  
Q3W group.
• The QLQ-C308 was administered at baseline and day 1 of each treatment cycle. 
• The QLQ-C30 assesses HRQoL over the past week using a Global Health Status/
HRQoL scale and across functional domains (physical, role, cognitive, emotional,  
and social functioning) and symptoms (fatigue, pain, nausea/vomiting, dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial difficulties).
 - Scores range from 0 to 100; high scores on functional domains and low scores on 
symptoms reflect better outcomes.
 - A change ≥10 points from baseline is considered clinically meaningful.9
• Mixed-effects repeated measures models (MMRM) estimated changes from baseline 
to each cycle on all QLQ-C30 scales; results are expressed as least squares (LS) 
mean and standard error (SE).
 - The model included fixed effects of treatment, visit, treatment-by-visit interaction, 
and baseline value.
• Changes from baseline in pain were also stratified by clinical responders, defined by 
ORR assessed by independent central review, and clinical non-responders (stable or 
progressive disease).
• For patients with data from baseline to cycle 6 and cycle 12, proportions with 
clinically meaningful (≥10 points) improvement or worsening, or stability (<10 points) 
on each item was determined.
• Kaplan–Meier (KM) survival analysis was used to estimate time to first clinically 
meaningful change in QLQ-C30 pain score and its relationship to tumor response  
in patients who had baseline pain scores that allowed for at least a 10-point change.
Results
• Demographic characteristics of enrolled patients (N=193) were generally similar 
across treatment groups (Table 1).
